Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/11817| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Cvetkovska, Emilija | en_US |
| dc.contributor.author | Kuzmanovski, I | en_US |
| dc.contributor.author | Babunovska, Marija | en_US |
| dc.contributor.author | Boshkovski, Bojan | en_US |
| dc.contributor.author | Aleksovska, Katina | en_US |
| dc.contributor.author | Trencevska Kiteva, Gordana | en_US |
| dc.date.accessioned | 2021-04-12T09:04:56Z | - |
| dc.date.available | 2021-04-12T09:04:56Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.uri | http://hdl.handle.net/20.500.12188/11817 | - |
| dc.description.abstract | The choice of antiepileptic drug is typically based on seizure type, and there is no evidence for superior effectiveness or potential deterioration of particular antiepileptic drug in specific etiologic subgroups. The aim of the study was to identify etiological factor(s) associated with increased risk of seizure aggravation with levetiracetam (LEV). | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Lippincott, Williams & Wilkins | en_US |
| dc.relation.ispartof | Clinical Neuropharmacology | en_US |
| dc.title | Levetiracetam-Induced Seizure Aggravation in Patients With Focal Cortical Dysplasia | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | 10.1097/WNF.0000000000000304 | - |
| dc.identifier.volume | 41 | - |
| dc.identifier.issue | 6 | - |
| item.fulltext | No Fulltext | - |
| item.grantfulltext | none | - |
| crisitem.author.dept | Faculty of Medicine | - |
| crisitem.author.dept | Faculty of Medicine | - |
| Appears in Collections: | Faculty of Medicine: Journal Articles | |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.